High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma.

Trial Profile

High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2014

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Jan 2013 Planned End Date changed from 31 Jul 2012 to 1 Jul 2016 as reported by ClinicalTrials.gov.
    • 11 Jul 2012 Planned end date changed from 1 Jul 2018 to 31 Jul 2012 as reported by ClinicalTrials.gov record.
    • 11 Jul 2012 Additional lead trial centre, primary endpoints and actual initiation date (Jun 2012) added and planned number of patients changed from 24 to 30 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top